Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Linde PLC (LIN) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Alnylam Pharmaceuticals, Inc. vs Linde PLC — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $303 (market cap $39.89B), while Linde PLC trades at $531.24 (market cap $244.95B). The key difference: Linde PLC is far larger — about 6.1× Alnylam Pharmaceuticals, Inc.'s market cap, and Linde PLC pays a 1.21% dividend while Alnylam Pharmaceuticals, Inc. pays none. Which is the better fit depends on your goals.
| ALNY | LIN | |
|---|---|---|
Market Cap | $39.89B | $244.95B |
Sector | Health | Basic Materials |
52-Week High | $491.22 | $546.64 |
52-Week Low | $278.09 | $389.38 |
Enterprise Value | $38.15B | $267.30B |
Dividend Yield | — | 1.21% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ALNY trades at $298.76, down 4.49% today, but maintains a bullish technical outlook with strong support at $290. The company reported robust revenue growth to $3.71 billion in 2025, turning profitable with net income of $313.75 million. Analyst consensus is strongly bullish with a $429.50 price target, supported by positive news on drug pipelines and AI partnerships.
Outlook remains positive driven by expanding product portfolio and strategic collaborations, though risks include clinical trial outcomes and high valuation multiples. Earnings beats in recent quarters reinforce growth trajectory, but dependence on key drug Amvuttra and competitive pressures warrant monitoring for sustained shareholder value.
Linde PLC (LIN) trades at $529.79, up 0.8% today, with strong analyst support (24 buy, 4 hold) and a consensus price target of $560. The stock shows consistent earnings beats, with Q1 2026 EPS of $4.33 exceeding estimates, and robust fundamentals including a 20.44% net margin and 18.49% ROE. Technical indicators are bullish overall, with the current price near resistance at $529.
Outlook remains positive due to steady revenue growth, high profitability, and shareholder returns via dividends. Risks include elevated valuation multiples (P/E 35.13) and rising debt-to-asset ratio. The stock offers a balanced opportunity for growth investors, supported by strong institutional sentiment and operational execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.
Read more on ALNY →About Linde PLC
Linde is the largest industrial gas supplier in the world, with operations in over 100 countries. The firm's main products are atmospheric gases (including oxygen, nitrogen, and argon) and process gases (including hydrogen, carbon dioxide, and helium), as well as equipment used in industrial gas production. Linde serves a wide variety of end markets, including chemicals, manufacturing, healthcare, and steelmaking. Linde generated approximately $31 billion in revenue and $5 billion in GAAP operating profit in 2021.
Read more on LIN →
